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Chronic constriction injuryThepost-transcriptional regulatormolecules,microRNAs, have emerged as important biomarkers andmodulators of
numerous pathophysiological processes including oncogenesis and cardiovascular diseases. Recently, a signiﬁcant
number of dysregulations in microRNAs have been reported in patients suffering from painful disorders such as
complex regional pain syndrome, cystitis-induced chronic pain and irritable bowel disorder, in both affected tissues
and the circulation. Moreover, microRNAs are known to be involved in pain processing based on several recent
ﬁndings in animal models of inﬂammatory and neuropathic pain.
Thebasis of this reviewwas to cover and summarize available articles in English encompassing “microRNA and pain”.
In animal pain models widespread microRNA modulation is present and manifests on multiple levels i.e.: the
dorsal root ganglia, the spinal dorsal horn and the brain. Numerous functional in vivo studies have found that dys-
regulatedmicroRNAs are involved in the post-transcriptionalmodulation of genes implicated in pain generation
and maintenance. Lastly, a few animal studies have delivered promising results as to the possibility of applying
microRNAs as therapeutics to alleviate established pain and several clinical studies have highlighted the poten-
tial in applying microRNAs as biomarkers in painful conditions such as complex regional pain syndrome and ﬁ-
bromyalgia. This review brieﬂy introduces the basics of microRNAs, their biogenesis and function, and mainly
focuses on the recent advances made in understanding the role of microRNAs in relation to pain processing
and painful conditions. It also provides an overview of widely diverse methodological approaches and results
with a potential for future implications of microRNAs in the diagnosis and treatment of pain.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Human disorders associated with signiﬁcant pathological pain such
as osteoarthritis (OA), post-herpetic neuralgia, diabetic polyneuropathy
andmigraine are all highly prevalent, reduce life quality for affected pa-
tients and thus represent a large socioeconomic burden (Berger et al.,
2004; Manack et al., 2011; Pérez et al., 2012; Phillips, 2003). Moreover,
these conditions share a high incidence of co-morbidities and largely
suboptimal treatment possibilities (Finch, 2013; Pérez et al., 2012).
Signiﬁcant progress has been made in terms of identifying matrices in-
volved in normal and pathological pain processing as well as under-
standing the molecular mechanisms underlying nociception and pain
(Pace et al., 2006). Similarly, advances have been made in understand-
ing the causes underlying pain chroniﬁcation (Seifert and Maihöfner,
2011). Within the last six years, accumulating evidence has suggested
that a class of small non-coding inhibitory RNAs known as microRNAs
(miRNAs) play an important role in regulating pain-processing within a
wide range of experimental models and clinical pain disorders (see
Fig. 1) (Kynast et al., 2013a; Lutz et al., 2014; Niederberger et al., 2011).
This review aims at presenting the advances made in understanding
the role of miRNAs as micro-modulators, biomarkers and potential ther-
apeutic entities of painful conditions.Fig. 1. Clinical pain condition and in vivo painmodels accompanied by signiﬁcant miRNAmodu
are represented. Blue = animal surrogate model of pain, red = clinical pain conditions, orangSearch methodology and structure
Based on the PubMed entry: “(Pain OR nociception) AND (miRNA OR
microRNA)”, with no time limit on the 24th of April 2014, 120 indexed
articleswere identiﬁed, demonstrating that research onmicroRNAs in re-
lation to pain is still very limited. All publications were curated based on
title and abstract; from those, 49 were found relevant and included,
whereas 69 were excluded. It is important to note that this particular
search strategy is not intended to cover all miRNA alterations in diseases
that can give rise to pain per se. For example, various cancers, such as
glioblastoma, involve extensive miRNA dysregulation and can result in
excruciating pain (Edvardsson andPersson, 2012), however, this example
and similar areas are not dealt with in this review since the primary focus
of the literature in such ﬁelds are inherently related to the miRNA-
involvement in oncogenesis and not pain processing (Edvardsson and
Persson, 2012; Møller et al., 2013). The studies included herein can be
broadly subdivided into the following 3 categories of which several over-
lap: 1) explorative studies ofmiRNA-alterations induced bymodeled pain
conditions in vivo, i.e. both pain related to inﬂammation and neuropathy,
2) studies investigating miRNA alterations in patients suffering from var-
ious conditions related to pain, and 3) studies that explore the functional
properties of one or more speciﬁc miRNA in relation to a particular painlation and the tissue(s) where themiRNA changes manifest. Typical pathological locations
e = animal surrogate model of pain and clinical pain conditions.
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the commonly perceived etiology of pain models as either inﬂammatory
or neuropathic pain (Pace et al., 2006). Studies of miRNA dysregulation
in patients with conditions associated with signiﬁcant recurrent or
chronic pain are classiﬁed according to various somatic origins.
MicroRNA structure and function
miRNA is a novel class of non-coding single-stranded RNA of 19–24
nucleotides with the ability to modulate a large proportion of the
genome post-transcriptionally (Bartel, 2009; Lagos-Quintana et al.,
2001). They bind to the 3′ untranslated region (UTR), or occasionally
5′ UTRs, of the multiple mRNA targets to which they exhibit imperfect,
or sometimes, perfect complementarity. This enables one speciﬁc
miRNA to inhibit the translation of multiple genes (Thomson
et al., 2011; Ørom et al., 2008). The ﬁrst miRNA was discovered in
Caenorhabditis elegans in 1993 and named: lin-4 (Lee et al., 1993).
Later, upon discovery of let-7, which was found conserved in several
species, miRNA-regulation was recognized as an omnipresent entity in
eukaryotes (Pasquinelli et al., 2000; Reinhart et al., 2000).
The biogenesis of miRNA starts with the transcription of miRNA-
genes by RNA polymerase II, giving rise to pri-miRNA, which is then
poly-adenylated, upon which it is cleaved by Drosha to become
pre-miRNA and transported out of the nucleus by Exportin-5 (Yi et al.,
2003). Dicer then cleaves the pre-miRNA of which normally only one
strand, the guide-strand, ismerged into the RNA-induced silencing com-
plex (RISC). RNA-silencing post-transcriptionally is facilitated by the
binding of miRNA attached to RISC, to the respective mRNA 3′ UTR,
resulting in translational inhibition (Winter et al., 2009). SomemiRNAs
are selectively excreted via lipoproteins or micro-vesicles, functioning
as a mode of intercellular communication, a notion that is of crucial im-
portance in relation to the potential of miRNA as biomarkers (Chen
et al., 2012; Stoorvogel, 2012). For more information onmiRNA biogen-
esis, please refer to the available comprehensive reviews (Tran and
Hutvagner, 2013; Winter et al., 2009).
Today,miRNAs are established, as crucialmicro-modulators of normal
cellular homeostasis and accordingly, the dysregulation of miRNAs has
been associated with a wide range of pathological conditions such as
cancer (Calin and Croce, 2006; McManus, 2003), cardiovascular diseases
(Vickers et al., 2014), and neurodegenerative disorders (Abe and Bonini,
2013). The expression of miRNAs in pathological specimens or bioﬂuids
normalized to corresponding non-pathologic samples is under extensive
scientiﬁc investigation (Jia et al., 2014). Selected miRNAs are subse-
quently subjected to in silico and/or in vitro validation to elucidate
their speciﬁc target genes. Accordingly, studies on miRNAs in relation
to pain are rapidly emerging with a main focus on individual miRNAs,
their role in various conditions and whether silencing/mimicking
them could be a potential treatment strategy. In addition, the applica-
tion of miRNAs as diagnostic tools in an array of diseases, including
painful conditions, identiﬁcation of patients at risk for development of
e.g. chronic pain conditions and the follow-up of the treatment course
with conventional drugs are under extensive investigation (Chen
et al., 2014; Im et al., 2012; Willemen et al., 2012).
Molecular mechanisms of pain: a role for microRNAs?
Multiple polymorphisms, affecting genes involved in neuronal signal
transduction, have been associated with altered pain response pheno-
types (James, 2013). These polymorphisms most predominantly, affect
genes involved in: 1) action potential generation e.g. the Na+-channel
SCN9A, 2) signal transmission e.g. the serotonin related SLC6A4, and 3)
endogenous pain modulation e.g. the μ-opioid receptor 1 (MOR1)
(James, 2013; Reyes-Gibby et al., 2007). However, the overall prevalence
of these and similar genotypes remains low when compared to the high
prevalence of chronic pain conditions without a hereditary etiology. Thishighlights the great importance in pathological pain mechanisms not re-
lated to the genomic layout (Breivik et al., 2006; Houlden et al., 2006).
Central and peripheral sensitization
Alteration in protein expression is one of the main characteristics in
development of a long-term hyper-excitability of peripheral nociceptive
and central neurons, which can contribute to development or mainte-
nance of chronic pain (Gold and Gebhart, 2010). As such, the process is
inherently subject to potential regulation by miRNAs, centrally as well
as peripherally.
In the periphery, inﬂammatory mediators such as prostaglandin E2
(PGE2), interleukin-1 beta (IL-1β), tumor necrosis factor alpha (TNFα)
release from the immune cells, keratinocytes, growth factors such as
granulocyte–macrophage colony-stimulating factor, nerve growth factor
(NGF) and neuropeptides such as calcitonin gene-related peptide
(CGRP), substance P and histamine from local nociceptors, are involved
in development or maintenance of hyperalgesia (Gangadharan and
Kuner, 2013). This inﬂammatory soup prompts activity in multiple gene
pathways includingMAPK3 and JAK-STAT-signaling and recruitsmultiple
downstream enzymes such as phospholipase C and phosphoinositide
3-kinase. This causes phosphorylation and de novo transcription of no-
ciceptive molecules such as transient receptor potential cation channel
subfamily V member 1 (TRPV1) and Nav1.8, ultimately leading to hyper-
excitability of the nociceptive Aδ- and C-ﬁbers (Gold and Gebhart, 2010;
Julius and Basbaum, 2001).
Central sensitization is caused by synaptic plasticity, activation of
glial cells, decreased signal transmission thresholds and decreased en-
dogenous modulation (Sandkühler, 2009; Scholz and Woolf, 2007;
Woolf, 2011). Excitatory synaptic communication between ﬁrst
order neurons and spinal cord neurons is largely facilitated by the
neurotransmitter glutamate and modulated by factors such as CGRP
and brain-derived neurotrophic factor (BDNF). Accordingly, post-
synaptic glutamatergic receptors play an important role in modulating
synaptic transmission following persistent nociceptive activity (Ji
et al., 2003). Changes in spinal function include long-term potentiation
of synapses as well as an increase in neuronal and glial hyper activity or
hyper responsiveness in the spinal dorsal horn (SDH), leading to overall
increased pain sensitivity (Ji et al., 2003; Sandkühler, 2009). In this rela-
tion, it is now established that signiﬁcantmiRNAalterations occur in the
SDH and the DRG under both inﬂammatory and neuropathic pain
conditions.
MicroRNA facilitated regulation of pain genes
Importantly, genetic, epigenetic and transcriptional alterations
manifest on a protein-level and considering that N60% of themammalian
genes are miRNA-targets, it is inherent that miRNAs are involved in the
post-transcriptional regulation of proteins crucial in pain processing
pathways (Friedman and Farh, 2009). In accordance, the dysregulation
of miRNAs targeting key regulators of pain processing such as
γ-aminobutyric acid-α1 (GABAα1) (Sengupta et al., 2013), cyclooxy-
genase 2 (Akhtar and Haqqi, 2012; Park et al., 2013), TRPV1 (Li et al.,
2011) and multiple Na+ and Ca2+-channels (Favereaux et al., 2011; Li
et al., 2011; von Schack et al., 2011) has been observed in various surro-
gate models of pain. Similarly, it has been shown that miR-23b regulates
the expression of MOR1 (Ni et al., 2013) and that opioid-tolerance asso-
ciated with prolonged morphine-administration is potentially a conse-
quence of miR-23b upregulation, thus extending the role of miRNA to
involve modulation of endogenous analgesic mechanisms (Wu et al.,
2008). This highlights the importance of understanding themechanisms
behind the transition from acute physiological pain to pathological
chroniﬁcation, and in the context of this review particularly mapping
to which extend miRNA-induced transcriptional repression of genes is
involved in pain pathophysiology.
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MicroRNAs involved in acute and prolonged inﬂammatory pain
A number of different in vivo models of inﬂammation have been
used to investigate the role of miRNA in inﬂammatory pain processing.
Generally, widespread miRNA alterations are observed upon pain induc-
tion (see Table 1). In a study by Zhao et al. (2010) itwas shown that Dicer
knockout mice had an attenuated pain response to inﬂammation
assessed by carrageenan injection into the hind paw, highlighting that
miRNAmodulation may predominantly constitute a detrimental mecha-
nism in the context of inﬂammation induced pain andhyperalgesia (Zhao
et al., 2010). This section highlights ﬁndings pertaining to the role of
miRNA modulation upon induced inﬂammation.
To date, four studies using Freund's complete adjuvant-induced
(CFA) inﬂammatory hyperalgesia have been published. In a
pioneering study in 2007, it was shown that inﬂammation induced
by injection of CFA into the masseter muscle of rats caused
signiﬁcant downregulation of 7 different miRNAs (see Table 1) in
the mandibular branch of the trigeminal nerve, amongst them was
miR-124 widely described as a key miRNA in pain-processing (Bai
et al., 2007). Also using CFA, Kusuda et al. (2011) applied a different ap-
proach only investigating four preselected brain-speciﬁc miRNAs of
which miR-1 and miR-16 expression was markedly downregulated for
7 days, but surprisingly upregulated in the SDH along with miR-206,
24 h after induction. The same year, miR-143was shown to be downreg-
ulated in the DRG upon CFA-induction but notably not in a neuropathic
pain model applying sciatic nerve transection (Kusuda et al., 2011). The
authors suggested Vcan1/2, known tomodulate neurogenesis, as a puta-
tive target based on a corresponding ipsilateral increase in mRNA, but a
luciferase-based target validation was not performed (Kusuda et al.,
2011). Most recently, it was conﬁrmed thatmiR-134, previously demon-
strated to be decreased under neuropathic conditions (Bai et al., 2007),
was downregulated in the DRG upon inﬂammatory induction with CFA
and that it was inversely correlated with MOR1-expression. The study
subsequently applied a luciferase-assay to validate MOR1 as a target of
miR-134 elucidating a potential endogenous pain modulation mecha-
nism and highlighting a novel therapeutic opportunity (Ni et al., 2013).
MicroRNAs in animal models of osteoarthritis
Several studies have used animal models of OA to study the miRNA
changes in associationwith the pathogenesis of this prevalent andpainful
condition. Firstly, a prominent increase inmiR-155 in synovial ﬁbroblasts
and monocytes was revealed in patients with rheumatoid arthritis (RA)
(Stanczyk et al., 2008). It was later discovered that miR-146a was signif-
icantly increased in peripheral blood mononuclear cells in RA (PauleyTable 1
Overview of results from studies onmiRNAmodulation in animal surrogate models of inﬂamm
validatedmRNA targets are included. The abbreviation behind individual highlightedmiRNAs d
horn, DRG = dorsal root ganglion, and ACC = anterior cingulate cortex.
Study Pain model Highlighted m
(sample origin
Bai et al. (2007) CFA-induced trigeminal pain miR-10a, miR
miR-124, miR
Li et al. (2011) Inﬂammatory joint pain miR-146a↓ (D
Tam Tam et al. (2011) CFA-induced pain miR-143↓ (DR
Kusuda et al. (2011) CFA-induced pain miR-1↑, miR-1
miR-1↓, miR-1
Poh et al. (2011) Facial inﬂammation miR-155↑, mi
Willemen et al. (2012) IL-1β-induced inﬂammatory hyperalgesia miR-124↓ (SC
Xu et al. (2012) IL-1β-induced inﬂammation in chondrocytes miR-194↑ (JC)
X. Li et al. (2013) Surgically induced joint pain miR-146a, mi
Kynast et al. (2013b) Formalin-induced inﬂammatory pain miR-124a↓ (S
Ni et al. (2013) CFA-induced pain miR-134↓ (DR
Park et al. (2013) Inﬂammatory joint pain miR-558↓ (JC)
Pan et al. (2014) CFA-induced pain miR-219↓ (SCet al., 2008). Elaborating on these results, Li et al. (2011) used the MIA
OA-model analyzing miRNA-expression both in the DRG and the SDH
and analyzed miR-146a modulation in human synoviocytes (Li et al.,
2011). Surprisingly, in rodent models of OA a steep decrease in miR-
146a expression in both the DRG and SDH was seen (as opposed to the
known upregulation in peripherally affected cells). Expanding on that
ﬁnding, the inﬂuence of miR-146a was investigated applying transient
transfection ofmiR-146a in astrocytes andmicroglia, resulting in a signif-
icant decrease in pro-inﬂammatory transcripts such as: TNFα, COX2,
nitric oxide synthase (iNOS) and interleukin 6 (Li et al., 2011). In a
study comparing cultured chondrocytes from healthy and OA donors
miR-558 was found to have signiﬁcantly decreased in the latter. The
study further showed that miR-558 deﬁciency is inducible by IL-1β and
conﬁrmed COX2 as a direct target mRNA, highlighting its potential im-
portance in joint inﬂammation (Park et al., 2013). The same group also
used a surgical animal model of OA analyzing miRNA-expression both
in the DRG and the SDH, here, a signiﬁcant reduction in the expression
of miR-146a andmiR-183was found (X. Li et al., 2013). This ﬁnding con-
curred with increased mRNA levels of a number of pro-inﬂammatory
mediators such as NFκΒ, TNFα and IL-1β, but luciferase validation was
not conducted on these potential targets. Interestingly, the study con-
ducted a series of loss/gain of function studies on microglia (BV2 cell
line) and astrocytes supporting the notion of miR-146a as being a key
regulator of inﬂammation, as previously reported by the same group (Li
et al., 2011).
MicroRNAs as potential therapeutic targets for inﬂammation
miR-124 has been found centrally downregulated in two studies ap-
plying different models of peripheral inﬂammatory hyperalgesia;
intraplantar IL-1β-injection and formalin application and is validated
to target MeCP2, previously implicated in nociception (Kynast et al.,
2013b;Willemen et al., 2012). Interestingly, miR-124 appears tomodu-
late the reactivity of microglia promotingM1 toM2 switch; thus poten-
tially decreasing central sensitization (Willemen et al., 2012). When
applied intravenously miR-124 and anti-miR-124 caused decreased
and increased pain behavior, respectively, albeit only signiﬁcantly in a
subset of the assessment timeframe (Kynast et al., 2013b). Other
known centrally acting miRNA alterations include upregulation of
miR-155 and miR-233 in the prefrontal cortices of rats upon
carrageenan-facilitated facial inﬂammation (Poh et al., 2011). Within
visceral inﬂammation, a very recent study investigated modulation of
miRNA in the developing spinal cord following neonatal cystitis in a
rodent-model applying zymosan. A steep increase of miR-181a
was revealed concomitantly with an apparent repression of the
GABAAα1-subunit. Subsequent administration of the GABAA-receptor
agonist, muscimol, did not attenuate the viscero-motor response (VMR)atory pain. Superscript numerals annotate a miRNA and its target gene(s). Only luciferase-
enotes the origin of the sample: HC = hippocampus, SC = spinal cord, SDH = spinal dorsal
iRNAs
)
Central/peripheral Aberrant
miRNAs
Luciferase-validated
targets
-29a, miR-98, miR-99a,
-134, miR-183↓ (TG)
Both 7
RG, SDH)/miR-146a↑ (JC) Both 1
G) Peripheral 1
6↑, miR-206↑ (DRG)
6↓, miR-206↓ (SDH)
Both 3
R-233↑ (PC) Central 1
M) Central 1
Peripheral 1 SOX5
R-183↓ (DRG) Peripheral 9
DH) Central 1 MECP2
G) Peripheral 1 MOR1
Peripheral 1 COX2
) Central 1 CAMK2G
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induced adult rats the drug produced signiﬁcant decrease in VMR
(Sengupta et al., 2013). The authors concluded that it is likely that
miR-181a is directly involved in toning spinal cord inhibition,
unmasking excitatory pathways to facilitate prolonged or even chronic
pain and hyperalgesia (Sengupta et al., 2013). Very recently, Park et al.
(2014) reported that extracellular miR-let-7b induces inward currents
in rat DRG through coupling between Toll-like receptor-7 and the noci-
ceptive ion-channel transient receptor potential cation channel sub-
family A. Furthermore, the study elucidated a direct nociceptive effect
of miR-let-7b in vivo, documented that miR-let-7b is released from
nociception neurons upon activation, and showed a reduction in
formalin-induced pain by concomitant administration of miR-let-7b-
inhibitor (Park et al., 2014). This report indicates that circulatory
miRNAs could be as physiologically relevant as intracellular miRNAs
and highlights their biomarker potential.
MicroRNAs involved in neuropathic pain
Lesions to the somatosensory nervous system frequently give rise to
neuropathic pain, generally classiﬁed as either central or peripheral. It is
estimated that≈8% of theWestern population suffers fromoneormore
subcategories of painful neuropathywith diabetic small-ﬁber neuropathy
being themost common subetiology (Torrance et al., 2006). Several stud-
ies investigating changes inmiRNA expression upon induced neuropathy
in rodent models have demonstrated a signiﬁcant dysregulation in
numerous miRNAs (see Table 2). A study by Genda et al. (2013) found
that 111 miRNAs were signiﬁcantly modulated in the SDH after chronic
constriction injury (CCI) in mice, but no further functional characteriza-
tionwas performed (Genda et al., 2013). Illustrating the lack of consolida-
tion in this research ﬁeld, a recent study, also using CCI was unable to
show any signiﬁcant difference between CCI- and sham-operated mice
(Brandenburger et al., 2012). An early studyutilizing a sciatic nerve injury
model in mice investigated both the differential expression of miRNA in
dorsal root ganglion (DRG) neurons compared to scam injured mice,
and also the effect of nerve injury on the proteins involved inmiRNA bio-
synthesis. While subunits of the RISC were highly upregulated, levels of
various p-body machinery proteins differed signiﬁcantly between
groups, indicating that not only miRNA-deregulation but also regulatory
proteins involved in the miRNA-processing pathway could be ofTable 2
Overview of results from studies on miRNA modulation in animal surrogate models of neurop
individual highlightedmiRNAs denotes the origin of the sample: TG = trigeminal ganglion, SDH
chondrocytes, and PC = prefrontal cortex.
Study Pain model Highlighted miRNAs/(sample o
Aldrich et al. (2009) Spinal nerve ligation miR-96↑, miR-182↑, miR-183↑
Liu et al. (2009) Contusive spinal cord injury miR-137, miR-181a, miR-219-2
miR-21↑ (all SDH)
Nakanishi et al.
(2010)
Spinal cord injury miR-223↑, miR-124a↓ (SC)
Imai et al. (2011) Sciatic nerve lesion miR-34c↓, miR-200b↓, miR-429
Favereaux et al.
(2011)
Spinal nerve ligation miR-103↓ (DRG)
Kusuda et al. (2011) Spinal nerve ligation and
axotomy
Axotomy: miR-1 (↑SDH/↓DRG)
miR-206↑ (SDH)
Spinal nerve ligation: miR-1↓ (
(DRG)
Wu et al. (2011) Sciatic nerve crush miR-124↓, miR-221↑, miR-142-
miR-21↑ (All DRG)
Im et al. (2012) Spinal cord injury miR-23b↓ (SDH)
Genda et al. (2013) CCI miR-21, miR-221, miR-500 (all
Arai et al. (2013) CCI miR-125b↓, miR-132↓ (both HC
H. Li et al. (2013) CCI miR-341↑ (DRG), miR-203↓ (SD
miR-541-5p↓ (SDH),
miR-181a-1-3p↓ (SDH)
Chen et al. (2014) CCI miR-96↓ (DRG)
(Li et al., 2014) Bilateral constriction injury miR-203↓ (SDH)importance in the peripheral response to injury (Wu et al., 2011). In a
L5 spinal nerve ligation model, 63 miRNAs were found dysregulated, 59
of which were concomitantly dysregulated in the ipsilateral L4 DRG sug-
gesting that miRNA changes in adjacent uninjured afferents may also
contribute to the development and continuation of neuropathic pain.
The study did not elaborate further on these projectedmiRNA alterations
and their underlying cause (von Schack et al., 2011). Another recent
study using a spinal nerve ligation model utilized genome-wide miRNA
sequencing in two genetically similar rat strains displaying opposite re-
sponses to neuropathic injuries, i.e. pain-prone and pain-resistant. The
study discovered a 3-miRNAs signature being highly downregulated in
the pain-prone rat strain and used in silico target prediction to associate
themiRNAs rno-miR-30d-5p and rno-miR-125b-5pwith the neuropathic
pain related genes, TNF and BDNF (Bali et al., 2014).
Several studies have investigated neuropathy-inducedmiRNA alter-
ations at the central level. Imai et al. (2011) found that sciatic nerve
lesion in mice induced signiﬁcant downregulation of miR-200b and
-429 in post-synaptic neurons of nucleus accumbens and that this
downregulation corresponded with increased levels of DNA (cyto-
sine-5)-methyltransferase 3A (DNMT3a). The authors proposed
that the DNMT3a increase associated with decreased levels of miR-
200b and -429 is involved in the generation of dysfunction of the
mesolimbic motivation/valuation circuitry linking prolonged nocicep-
tive stimuli with co-morbid conditions such as anxiety and sleep distur-
bances (Imai et al., 2011). In a similar study using CCI in mice, the
hippocampal formationwas analyzed using TaqMan low-density arrays
and 51 miRNAs were found to be signiﬁcantly altered compared to con-
tralateral sham surgery.With complementary qRT-PCR the study investi-
gated the downregulation of miRNAs miR-125b and -132 at days 7 and
15 post injury but conducted no miRNA target-validation (Arai et al.,
2013). In a recent study using bilateral CCI in rats and performing
miRNAmicroarray analysis on DRG, SDH, hippocampus and anterior cin-
gulate cortex, a signiﬁcant upregulation of miR-341 was observed in
DRG-neurons and a downregulation of miR-181a-3p, -203 and -541-3p
was observed in the SDH, demonstrating miRNA alterations in both
the CNS and PNS in response to chronic sciatic constriction. None of
these miRNAs was further functionally analyzed. In contrast to the
study by Arai et al. (2013), no signiﬁcant miRNAmodulations were ob-
served in the hippocampus, representing a substantial discrepancy in
the literature (H. Li et al., 2013).athic pain. Only luciferase-validated mRNA targets are included. The abbreviation behind
= spinal dorsal horn, DRG = dorsal root ganglion, SCM = spinal cordmicroglia, JC = joint
rigin) Aberrant
miRNAs
Central/
peripheral
Luciferase-validated targets
(all DRG) 3 Both
-3p, miR-7a↓, 269 Central
2 Central
↓ (all ACC) 17 Central
1 Peripheral CACNA1C, CACNA2D1,
CACNB1
, miR-16↑ (SDH),
DRG), miR-206↓
3 Both
5p↑, 4 Peripheral
Unspeciﬁed Central NOX4
DRG) 111 Peripheral
) 51 Central
H), 1 Central
1 Peripheral
Unspeciﬁed Central RAP1A
1 NB. Studies that include "endometriosis" and "microRNA".
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In the light of four recent studies, the outlook of applying anti-
miRNAs/miRNA-mimics to treat neuropathic pain and hyperalgesia
seems bright. In streptozotocin-induced diabetic neuropathy in rats, a
miRNA-construct targeting Navα-subunits was delivered by a herpes
simplex virus-based vector successfully reversing cold allodynia and
thermal and mechanical hyperalgesia (Chattopadhyay et al., 2012). In
another comprehensive study, intrathecal administration of miR-23b-
mimics signiﬁcantly alleviated mechanical and thermal hyperalgesia in
a mice model of spinal cord injury. Furthermore, miR-23b was shown
to target NADPH oxidase 4 (NOX4), an inﬂammation-promoting enzyme,
also known to decrease production of the inhibitory neurotransmitter
GABA through inhibition of glutamic acid decarboxylase (Im et al.,
2012). Similarly, miR-124 (which is highly expressed in quiescent
microglia) was shown to shift the M1/M2 balance towards the anti-
inﬂammatory M2 phenotype and to decrease mechanical hyperalgesia
and pain behavior in a spared nerve model in mice (Willemen et al.,
2012). Most recently, Chen et al. (2014) showed that CCI causes a
steep decrease of miR-96 in DRG neurons, coinciding with an increase
in Nav1.3, an ion-channel implicated in neuropathic hyper-excitability
and a predicted target of miR-96. Subsequently, the study proved intra-
thecal injections to be efﬁcient in alleviating both mechanical and ther-
mal hyperalgesia associated with the CCI procedure (Chen et al., 2014).
It is evident that miRNAs have a potential as speciﬁc biomarkers and
possibly therapeutic entities within neuropathic conditions and new
studies on functional miRNA characterization and exploration of deliv-
ery methodology could hold promise in future targeted therapy of neu-
ropathic pain.
MicroRNAs in clinical pain conditions
As described, it is evident that animal models of neuropathic and
inﬂammatory pain demonstrate widespread miRNA alterations and
furthermore that many of these alterations are detrimental to the
given condition (Chen et al., 2014; Genda et al., 2013). This section high-
lights novel ﬁndings on the implication of miRNAs from clinical painful
conditions with diverse characteristics and origin. In the context of in-
vestigating the link between miRNAs and pain processing, it is impor-
tant to note that particularly when it comes to clinical pain conditions
it is unclear to which extent miRNAs merely aggravate the underlying
pathogenesis subsequently leading to pain perception and not pain pro-
cessing itself.
The most comprehensive body of literature is available on the sub-
ject of knee arthritis, ﬁrst and foremost OA and RA. Human specimens
from patients clearly indicate that miRNAs are entwined in the patho-
genesis of RA and OA, potentially contributing to cartilage degeneration
and possibly even pain chroniﬁcation (Furer et al., 2010; Stanczyk et al.,
2008; Yu et al., 2011). It is beyond the scope of this review to summarize
the ﬁndings of miRNAs implicationwithin OA, RA and autoimmune dis-
eases in general (refer to Furer et al., 2010 for more on this particular
topic).
MicroRNAs in visceral pain conditions
In several visceral painful conditions such as irritable bowl syndrome
(IBS), bladder pain syndrome (BPS), endometriosis and cystitis-induced
chronic pain (CICP) miRNA dysregulation has been reported. In IBS, the
miRNA proﬁle appears to facilitate an increased permeability of the
gastrointestinal tract (Zhou et al., 2010). A noteworthy study by Verne
and colleagues (2010) demonstrated that miR-29a is markedly in-
creased in patients with IBS in intestinal biopsies and in a subset of
diarrhea-predominant IBS patients' miR-29a was found signiﬁcantly
upregulated in circulating miRNA-containing exosomes (see Table 3).
The study used a luciferase-reporter to validate that miR-29a targets
the glutamine synthetase gene GLUL, thus decreasing enterocyticglutamine levels and aggravating the increased intestinal permeability
(Zhou and Verne, 2011; Zhou et al., 2010). In a study of BPS, 31miRNAs
were differentially expressed and a direct correlation between the
increased expression of miR-449b and miR-500 concomitantly with
downregulation of the substance P receptor NK1-receptor was found
(Sanchez Freire et al., 2010). The authors suggested this to constitute a
miRNA-dependent adaptive mechanism to the prolonged NK1R overex-
pression which was previously described in BPS (Marchand et al., 1998;
Sanchez Freire et al., 2010). In endometriosis, characterized bymenstrual
cycle-dependent pelvic pain, a great deal of recent research has revealed
the inﬂuence of miRNAs. The ﬁrst study reporting widespread miRNA
dysregulation in endometriosis was published in 2007 (Pan et al., 2007)
and 45 studies have been published since then on that subject.1 Notably,
Hawkins et al. (2011) performed a full microRNAome analysis of
endometriosis patients and found 22 miRNAs to be dysregulated. The
study further investigated the highly upregulated miR-29c and eluci-
dated its ability to signiﬁcantly inhibit several important genes
involved in extracellular matrix function such as collagen type VII A1
(COL7A1). Lastly, the same study also validly pointed out the extensive
discrepancy present in terms of the speciﬁc miRNAs found across simi-
lar studies but ascribed it to methodological differences e.g. sampling
time in relation to menstrual cycle (Hawkins et al., 2011). In the highly
prevalent pain disorder, lower back pain, Zhao et al. (2014) investigated
one of the frequent underlying causes being intervertebral disc degen-
eration (IDD). Here, miRNA expression in the nucleus pulposus was
compared between IDD patients and acute intervertebral injury pa-
tients giving rise to a large miRNA signature, but no further analysis
was performed (Zhao et al., 2014).MicroRNAs as biomarkers in pain disorders
Investigating miRNAs as diagnostic and prognostic bioﬂuid-derived
biomarkers is well progressed in various ﬁelds, particularly oncology
and cardiology, but is novel in relation to pain conditions (Ahmad
et al., 2013; Kinet et al., 2013). Research in miRNAs are of great interest
in terms of biomarker potential since they are present in virtually all
bioﬂuids, exhibit more superior stability than mRNA and appear to be
highly sensitive to slight changes in various physiological processes
(Jung et al., 2010; Kemppainen et al., n.d.; Tomaselli et al., 2012).
In an innovative study by Orlova et al. (2011), whole blood samples
were taken from 41 patients with complex regional pain syndrome
(CRPS) and 20 controls upon which analysis of miRNA expression, cyto-
kines and numerous clinical parameters were conducted (see Table 3).
Unsurprisingly, cytokines such as CCL2 and VEGF were notably elevated
in the CRPS group compared to control and a CRPSmiRNA-signaturewas
evident. Interestingly, extensive correlation analyses revealed that
4 miRNAs (miR-296-5p, -532-3p, -361-3p and -30d) were positively
correlated with CRPS-associated pain level, miR-150 was correlated
with the occurrence of migraine within the CRPS patient cohort and
an extensive array of miRNAs was found to correlate with the levels of
circulating cytokines (Orlova et al., 2011). A recent study with a similar
design investigated the miRNA proﬁle of the cerebrospinal ﬂuid in
ﬁbromyalgia patients and identiﬁed 10miRNAs differentially expressed
between affected patients and healthy controls. Most notably, the study
found that decreased levels of miR-145-5p in the CSF were associated
with reported symptomatology i.e. pain intensity and fatigue (Bjersing
et al., 2013).
The prospect of applying miRNAs as bioﬂuid-derived biomarkers in
pain conditions is enticing due to their high speciﬁcity, e.g. circulating
miRNA-signatures have been ascertained to discriminate between
eccentric and concentric exercise (Banzet et al., 2013). However,
numerous obstacles are present when using circulating miRNAs: 1) it
remains unclear why and to which extent miRNAs are selectively
Table 3
Examples of painful disorders where serum microRNA aberrations are associated with symptomatology. *Notice that these are proposed endogenous control miRNAs, but are found
signiﬁcantly dysregulated. ↑/↓ = increase/decrease.
Reference Condition MicroRNA(s) Sample / sample size
Orlova et al.
(2011)
Complex regional pain
syndrome
(↓) miR-939, -25, -7c, -7a, -7b, -320b, -126, -629, -664, -320, -1285, -625,
-532-3p, -181a
(↑) RNU48*, RNU44*, miR-720, -1201
Whole blood/41 patients, 20 controls
Bjersing et al.
(2013)
Fibromyalgia (↓) miR-21-5p, 145-5p, 29a-3p, 99b-5p, 125b-5p, 23a-3p, 23b-3p, 195-5p,
miR-223-3p
Cerebrospinal ﬂuid/10 patients, 20 controls
Zhou et al.
(2010)
Irritable bowel syndrome (↑) miR-29a Serum micro-vesicles/19 patients, 10 controls
Wang et al.
(2013)
Endometriosis (↑) miR-199a miR-122
(↓) miR-145a-3p, -141-5p, -542-3p, -9-3p
Serum/10 patients, 10 controls (screening) | 60
patients,
25 controls (validation)
Beyer et al.
(2014)
Osteoarthritis (↓) let-7e, miR-454, -885-5p
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issues associated with sampling, particularly hemolysis and low isola-
tion yields, and 3) plasma miRNA expression is highly affected by vari-
ous hormonal and metabolic factors (Tomaselli et al., 2012).
Conclusion and future directions
Despite being a subﬁeld in its infancy, it is clear thatmiRNAalterations
are essential in a variety of pain models and in clinical conditions charac-
terized by severe pain (Kynast et al., 2013a). Until now studies have been
conducted either in animal painmodels or in fewer caseswithin a patient
cohort posing inherent limitations as to the translatability between these
two types of studies. The use of human surrogate models have been
beneﬁcial in improving understanding of pain processing by temporarily
recreating concise pain symptoms such as spontaneous burning pain,
heat hyperalgesia or cold allodynia (Andersen et al., 2014; Arendt-
Nielsen and Yarnitsky, 2009). Studies mapping the local and systemic
miRNA alterations likely associated with induced local inﬂammation in
widely used models such as the heat/capsaicin, ultraviolet B and NGF
models (Arendt-Nielsen and Yarnitsky, 2009) are warranted.
Within animal models of neuropathic and inﬂammatory pain such
as rodent spinal nerve ligation and CFA-induced inﬂammation, wide-
spread miRNA modulation is observed (Bai et al., 2007; Genda et al.,
2013). It appears that miRNA alterations occur more rapidly in response
to inﬂammatory pain, and some suggest it to be an adaptive mechanism
aimed at pain reduction, as opposed to miRNA alterations in response to
neuropathic pain suggested mainly to be a detrimental process (Bali and
Kuner, 2014; Gheinani et al., 2013). Despite the fact that numerous
miRNAs are frequently reported aberrantly expressed, onlymodest over-
lap between dysregulated miRNA such as miR-103 in neuropathy and
miR-146a in inﬂammation is present in the literature (Favereaux et al.,
2011; Li et al., 2011; Pauley et al., 2008; Yamasaki et al., 2009). Further re-
search is warranted to adequately elucidate whether this is a conse-
quence of limited published data or high speciﬁcity between miRNA
alterations between various pain conditions. Interestingly, a fewmiRNAs,
such as miR-183, have been found consistently downregulated in both
neuropathic and inﬂammatory pain conditions while others, such as
miR-1, have opposite responses between neuropathic and inﬂammatory
models and even within different neuropathic pain models (Bali and
Kuner, 2014; Kusuda et al., 2011).
Although administration of anti-miRs and miR-mimics has already
been successfully applied in animal models of neuropathic and inﬂam-
matory pain, it is necessary to obtain consistent knowledge about the
role of miRNAs in pain processing during various normal and pathologi-
cal pain conditions before any diagnostic or therapeutic utilization can be
accomplished (Chattopadhyay et al., 2012; Chen et al., 2014; Im et al.,
2012; Willemen et al., 2012). Frequently, a large number of miRNAs
are found dysregulated in a given condition (Genda et al., 2013). This
is, at the same time, an obstacle and also an opportunity. The obvious
challenge lies in increased complexity and choosing the most promisingmiRNA(s) for further investigation. To overcome this challenge several
strategies can be utilized: 1) the median absolute deviation can be
applied to assess the most differentially expressed miRNAs across sam-
ples in combination with statistical testing, 2) in silico target prediction
algorithms can be used to predict feasible targets relevant for pain pro-
cessing, and 3) speciﬁc promising miRNAs can be tested individually in
miRNA transfection studies. As for the opportunity related to the fact
that manymiRNAs are often found dysregulated in a given condition, in-
creased speciﬁcity is the primary gain. As such, miRNAs as biomarkers
are promising not only in terms of diagnosis, but also in relation to pa-
tient stratiﬁcation. A seemingly high level of speciﬁcity could hold prom-
ise in stratiﬁcation of heterogeneous patient populations, currently
difﬁcult to subcategorize. The literature is growing dramatically in
terms of reporting aberrantly expressed miRNAs in multiple pain condi-
tions; however, functionallywell-characterizedmiRNAs is highly lacking
and needs particular attention (Arai et al., 2013; Genda et al., 2013).
Another pronounced bottleneck is represented by the problem of
distributing miRNA-mimic or anti-miRNA to the target tissue, particu-
larly when it comes to deliveringmiRNAs across the blood brain barrier,
whichwould be relevant to formulate a centrally acting analgesic. Novel
results indicate a great potential of exosomes, already known to carry
microRNAs in cell-to-cell communication and to deliver siRNA to target
cells (Chen et al., 2012; Johnsen et al., 2014). This approachwas utilized
by Alvarez-Erviti et al. (2011), who applied exosomes expressing
neuron-speciﬁc targeting surface peptides by systemic injection. This
enabled cell speciﬁc delivery of the siRNA-cargo across the blood brain
barrier (Alvarez-Erviti et al., 2011). Although promising, some concerns
have beenmade as towhether exosomal cell-to-cell interaction is phys-
iologically relevant and whether exosome-carried therapeutics will
prove clinically feasible (Sverdlov, 2012).
Intricately, pain gives rise to miRNA alterations on multiple levels
(see Fig. 2). In circulation, miRNAs-signatures have been discovered in
e.g. IBS and CRPS-patients (Orlova et al., 2011; Zhou et al., 2010). In
local tissues miRNA dysregulation in response to pain involve residing
primary afferents, ﬁbroblasts and keratinocytes e.g. in post-operational
skin inﬂammation (Sun et al., 2012). Knowledge is scarce regarding the
purpose of circulatingmiRNAs and local cell-to-cell interactionsmediated
by miRNAs, but these ﬁelds are of great interest in regards to biomarkers
and potential formulation of topical analgesics, respectively. In the DRG
and the SDH widespread miRNA dysregulation has been documented in
response to both neuropathic and inﬂammatory pain and it is evident
that miRNA expression is selectively modulated between the SDH and
DRG neurons in response to the exact same injury. For instance, miR-16
expression was signiﬁcantly reduced in the DRG, but upregulated in the
SDH after CFA-induced inﬂammation in mice, i.e. exhibiting opposite ex-
pressional response between peripheral and central compartments
(Kusuda et al., 2011). Many of these studied miRNA-driven alterations
prompt the initiation or maintenance of a more excitable phenotype,
thus increasing the conductance of nociceptive stimuli (Chen et al.,
2014; Zhao et al., 2010). It is known that both microglia and astrocytes
Fig. 2. Locations ofmiRNA alterations in response to induced pain and painful disorders. The tables at each level list examples of well-investigatedmiRNAs and their correspondingmRNA
targets. MiRNA modulation is reﬂected in: the circulation, DRG neurons, SDH, glial cells and in several brain areas. DRG = dorsal root ganglion and SDH = spinal dorsal horn. *Not
validated with a luciferase-reporter assay.Red arrows denote miRNA up- and downregulation and the speciﬁed locations.
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these cells is correspondingly associated with CNS hypertrophy and in-
creased reactivity (Bhalala et al., 2012; Ponomarev et al., 2011). Circula-
torymiRNAs are also present in the cerebrospinalﬂuid and here speciﬁc
miRNAs have been linked to pain in ﬁbromyalgia patients (Bjersing
et al., 2013). Lastly, miRNA alterations have been mapped in several
brain matrices associatedwith higher pain processing in rodent models
of pain (Poh et al., 2011).
In summary, miRNAs are rapidly emerging as pivotal players in-
volved in pain from the ﬁrst single study in the ﬁeld in 2007 (Bai
et al., 2007) to 37 publications in 2013 alone. These small non-coding
RNA molecules represent promising potential biomarkers and thera-
peutic targets in a variety of human diseases, including pain conditions.
However, pronounced bench-to-bedside hindrances warrants further
studies before miRNAs can be applied clinically in pain patients for
prognosis, diagnosis, follow-up of the treatment course, and potentially
novel treatment strategies.
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